scispace - formally typeset
B

Bo Lu

Researcher at Ohio State University

Publications -  390
Citations -  24905

Bo Lu is an academic researcher from Ohio State University. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 58, co-authored 353 publications receiving 21823 citations. Previous affiliations of Bo Lu include Wuhan University of Technology & Wuhan University.

Papers
More filters
Journal ArticleDOI

Prospective Observational Cohort Study On Grading the Severity of Postoperative Complications in Global Surgery Research

Tom E.F. Abbott, +2587 more
- 08 Jan 2019 - 
TL;DR: It is unclear whether the Clavien–Dindo system can be used internationally in studies across differing healthcare systems in high‐ (HICs) and low‐ and middle‐income countries (LMICs).
Journal ArticleDOI

ATM polymorphism IVS62+60G>A is not associated with disease aggressiveness in prostate cancer.

Robert E. Lee Browning, +8 more
- 01 Jun 2006 - 
TL;DR: The results of this study indicate that this ATM polymorphism is not associated with the aggressiveness of prostate cancer in white men.
Journal ArticleDOI

Ohio's Medicaid Expansion and Unmet Health Needs Among Low-Income Women of Reproductive Age.

Thalia P. Farietta, +2 more
- 01 Dec 2018 - 
TL;DR: After Ohio’s 2014 Medicaid expansion the odds of low-income WRA having unmet healthcare needs was reduced and future research should examine outcomes after a longer period of follow-up and include additional measures, such as self-rated health status.
Journal ArticleDOI

Are retailers compliant with zoning regulations that ban tobacco sales near schools in Changsha, China?

Ling Wang, +5 more
- 01 Jul 2017 - 
TL;DR: Low enforcement of the regulation that bans tobacco retail sales near schools and high prevalence of tobacco displays that target children in Changsha, China are observed.
Journal ArticleDOI

Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?

Susan E Creary, +5 more
- 21 Jan 2016 - 
TL;DR: If HU is differentially used in children with clinically severe SCD, and if HU users have shorter length of stay (LOS), fewer intensive care unit (ICU) admissions, and fewer inpatient transfusions compared to nonusers, is determined.